Respiratory · Cough and Cold
The FDA's approval of Rubicon Research's ANDA220869 for Promethazine and Dextromethorphan positions the company favorably within the competitive cough and cold market. This development necessitates close monitoring of market dynamics and competitor strategies as Rubicon prepares for market entry.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/27/2026, 6:04:34 AM
Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval of Rubicon Research's ANDA220869 for Promethazine and Dextromethorphan positions the company favorably within the competitive cough and cold market. This development necessitates close monitoring of market dynamics and competitor strategies as Rubicon prepares for market entry. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 12 ranked evidence items (8 high-relevance).
Portfolio teams should assess the competitive landscape for cough and cold products and consider strategic positioning for Rubicon's offering. The strongest clinical anchor is vNOTES vs Laparoscopy: Respiratory Mechanics and Hemodynamics (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 4 competitive items passed relevance filtering for competitors with similar formulations.
The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status may enhance Rubicon Research's position in the cough and cold market, potentially impacting competitors with similar formulations.
Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda).
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourcevNOTES vs Laparoscopy: Respiratory Mechanics and Hemodynamics
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceRSV Immunisation Status in Queensland (Australia)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEndocarditis Clinical Awareness, Research, and Evaluation in Sweden
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of Oral Mucosal Pressure Injuries
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceENDO1000 - A UK-wide Endometriosis Research Project
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of AI-Assisted Respiratory Training on Pain, Fatigue and Respiratory Parameters in Patients After Open Heart Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceRoche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceMerck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNeoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceClinical research progress and challenges of vaccine for human papillomavirus-associated cancers.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAdvances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceResearch progress of ferroptosis in gynecological diseases.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval of Rubicon Research's ANDA220869 for Promethazine and Dextromethorphan positions the company favorably within the competitive cough and cold market. This development necessitates close monitoring of market dynamics and competitor strategies as Rubicon prepares for market entry.
Rubicon's entry into the market with this combination product could disrupt existing market shares and influence pricing strategies among competitors, potentially affecting overall revenue in the cough and cold segment.
The granting of AP status indicates a significant step towards market availability, but the final approval and subsequent market entry timeline will be critical for assessing compliance and strategic responses.
Monitor the final approval and market entry timeline for ANDA220869, as well as competitor responses.
Track for follow-up milestones; no immediate action required.